VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH-TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the fourth quarter and year ended December 31, 2014. Amounts, unless specified otherwise, are expressed in U.S. dollars.
In support of their on-going large randomized Phase 2b lupus nephritis clinical trial (“AURA-LV”), the Company announced on February 9, 2015 the initiation of an open label, exploratory study called AURION to assess short term predictors of response using voclosporin in combination with mycophenolate mofetil (MMF) in patients with active lupus nephritis (LN). AURION will examine biomarkers of disease activity at 8 weeks and their ability to predict response at 24 and 48 weeks.
Help employers find you! Check out all the jobs and post your resume.
In support of their on-going large randomized Phase 2b lupus nephritis clinical trial (“AURA-LV”), the Company announced on February 9, 2015 the initiation of an open label, exploratory study called AURION to assess short term predictors of response using voclosporin in combination with mycophenolate mofetil (MMF) in patients with active lupus nephritis (LN). AURION will examine biomarkers of disease activity at 8 weeks and their ability to predict response at 24 and 48 weeks.
Help employers find you! Check out all the jobs and post your resume.
